TD Cowen Keeps Buy Rating on Senseonics Holdings, Reduces Price Target to $15
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Source: Benzinga
Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like SENS with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on SENS
Wall Street analysts forecast SENS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SENS is 18.70 USD with a low forecast of 9.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.820
Low
9.00
Averages
18.70
High
31.00
Current: 6.820
Low
9.00
Averages
18.70
High
31.00
About SENS
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strong Performance of European High Growth Tech Companies, Genmab Reports $3.85 Billion Revenue
- Market Resilience: The pan-European STOXX Europe 600 Index rose by 0.77%, supported by strong economic data and earnings results, indicating a cautious optimism in the market despite mixed performances among major stock indexes.
- Genmab's Innovative Partnership: Genmab's strategic alliance with Anthropic aims to integrate AI into its R&D processes, enhancing the efficiency of its antibody product clinical developments, which is expected to solidify its leading position in oncology.
- LINK Mobility's Recovery Potential: Despite a 40.4% contraction in earnings growth, LINK Mobility Group Holding is projected to achieve an annual earnings growth of 71.1%, significantly surpassing the Norwegian market's expectation of 15%, highlighting its strong recovery potential.
- Sensirion's Technological Leadership: Sensirion Holding AG excels in sensor technology with a 5.9% annual revenue growth and a forecasted 25.8% earnings growth, with innovations in environmental monitoring technology further enhancing its market competitiveness.
Continue Reading
Senseonics (SENS) Reports Q4 2025 Revenue of ~$14.2M with 103% New Patient Growth
- Significant Revenue Growth: Senseonics reported preliminary unaudited Q4 2025 revenue of approximately $14.2 million and annual revenue of about $35.2 million, indicating strong market performance, with expectations for 2026 global net revenue to reach $58-$62 million, reflecting a growth of 65% to 76%.
- Innovative Patient Growth: The company achieved a remarkable 103% new patient growth in the U.S. during Q4, marking the largest addition of new patients in its history, primarily driven by effective direct-to-consumer marketing strategies, showcasing the effectiveness of its promotional efforts and enhanced brand influence.
- Gross Margin Expectations: Senseonics anticipates a gross margin of approximately 50% for 2026, which will further enhance its profitability and provide funding support for future investments and expansions, reflecting success in cost control and product pricing strategies.
- Enhanced Financial Transparency: The company plans to release its Q4 and full-year 2025 financial results on March 2, 2026, which will provide more financial details and bolster investor confidence in the company's future development, while also expecting a cash and cash equivalents balance of about $94.3 million as of December 31, 2025.
Continue Reading